Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance
Authors:
Open Access
- 1 December 2020
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 101, 24-28
Abstract
No abstract availableKeywords
Funding Information
- Instituto de Salud Carlos III
This publication has 25 references indexed in Scilit:
- Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of MicafunginAntimicrobial Agents and Chemotherapy, 2014
- Pharmacokinetics of anidulafungin during albumin dialysisCritical Care, 2014
- Molecular Identification and Antifungal Susceptibility of Yeast Isolates Causing Fungemia Collected in a Population-Based Study in Spain in 2010 and 2011Antimicrobial Agents and Chemotherapy, 2014
- Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltrationJournal of Antimicrobial Chemotherapy, 2014
- A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational expertsIntensive Care Medicine, 2013
- Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures beyond Two-Thirds or Three-FourthsAntimicrobial Agents and Chemotherapy, 2013
- ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patientsClinical Microbiology and Infection, 2012
- The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrataAntimicrobial Agents and Chemotherapy, 2012
- Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or CandidemiaAntimicrobial Agents and Chemotherapy, 2011
- In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida SpeciesAntimicrobial Agents and Chemotherapy, 2010